Examines how emicizumab affects muscles and joints in children with hemophilia A
Observes how emicizumab affects muscles and bones in children with hemophilia A.
Plain-language title generated from the registry record
Registry title: Effects of Emicizumab Treatment in Patients With Hemophilia A
Key facts
- Where
- Gaziantep, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for boys under 18 with severe hemophilia A who are about to start emicizumab treatment. It studies effects on muscles and joints.
- Age
- 1 Year to 18 Years (under 18)
- Sex
- Male only
- Disease stage
- Hemophilia A diagnosed by a physician, with a factor level of 1% (IU) or less.
- Earlier treatment
- No obstacles to starting emicizumab treatment given under the skin.
- Biomarker or test result
- Inhibitors can be positive or negative.
Main reasons for not taking part
- Children with a history of bleeding in the brain who have nerve or brain symptoms that would prevent taking part
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT07190118, who can take part
Where in Türkiye
- Hasan Kalyoncu UniversityGaziantep, TürkiyeContact: Tuğba GÖNEN, Asisst. Prof. Dr.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hasan Kalyoncu University
- Trial code
- NCT07190118
- Record updated
- 24 September 2025
- Original description
The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.Read full original descriptionShow less
Effects of Emicizumab Treatment on the Musculoskeletal System in Children With Hemophilia A: A Prospective Study
The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.
Inclusion: Children who are under 18 years of age,; Have been diagnosed with Hemophilia A by a physician,; Have a factor level of 1% (IU) or less,; Have inhibitors positive or negative,; Have no obstacles to starting subcutaneous (emicizumab) treatment,; Willing to participate in the study.
Exclusion: Children with a history of cerebrovascular bleeding who present any neurological findings that would prevent participation in the study.